TREATMENTS IN THE PIPELINE: 150 headlines: THIS PAGE IS UNDER CONSTRUCTION...SOME RECENT HEADLINES HAVE NOT BEEN TRANFERRED TO THIS NEW SITE

DR. TIMOTHY VOLLMER IS WRITING AN ARTICLE FOR US ON THE 5 TREATMENTS HE FEELS ARE MOST PROMISING...OUT OF ALL OF THE NEW MS TREATMENTS THAT WERE ANNOUNCED AT ECTRIMS: The 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis...September 27–30 in Madrid, Spain

ALERT #41 WILL BE SENT TO YOU THIS WEEKEND - Click here if you haven't requested our weekly MS Drug Alerts

HERE'S 27 NEW MS TREATMENTS WE'VE POSTED IN THE LAST 2 WEEKS:

SCROLL DOWN..BELOW THIS POST..FOR THE FULL STORY ON EACH HEADLINE:

1...TYSABRI HELPS COGNITION: Tysabri reduced the risk of sustained cognitive worsening by 43 percent, compared to placebo.....

2...CAMPATH: "Genzyme Says MS Drug Works Better Than Serono's Rebif"

3...ORAL FINGOLIMOD - FTY720: Presented at ECTRIMS
Oral FTY720 (Fingolimod) for Relapsing Multiple Sclerosis Shows Sustained Benefits for Up to 2 Years

4....NEW REBIF AUTO-INJECTOR: ECTRIMS Presentation on new-improved Rebif PLUS It's new auto-injector, which uses the thinnest needle of any treatment!!!
New Formulation Rebif for Relapsing Multiple Sclerosis Lowers Immunogenicity and Improves Tolerability

5...ORAL LAQUINIMODE BY TEVA: The NEW once-daily novel oral agent for relapsing remitting

6...ORAL FAMPRIDINE-SR BY SERONO: FDA fast-tracks Serono's oral MS drug Cladribine...
Patients who took Fampridine-SR moved 25 percent faster ontimed 25-foot walk, while patients getting a placebo improved 4.7 percent, Hawthorne

7...COPAXONE(R) Showed Sustained Benefit on Slowing Brain Tissue Damage in Multiple Sclerosis Patients
Data presented last week at the 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)

8...FATIGUE AND FUNCTIONAL DEFICIT IMPROVEMENT: Four-week Rehab Significantly Improves Fatigue and Functional Deficit in Multiple Sclerosis Patients: Presented at ECTRIMS
Fatigue and functional deficits in multiple sclerosis (MS) patients were significantly improved during 4 weeks of inpatient rehabilitation, researchers reported here at the 22nd Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS)....

9...SATIVEX - CANNABINOID-BASED DRUG: Savitex Appears Helpful for Spasticity in Multiple Sclerosis: Presented at ECTRIMS

10...MBP8298: New Drug in the Pipeline...A message from Ryan Giese

11...CDP323: NEW DRUG IN PIPELINE - Biogen Idec:
"Biogen Idec and UCB and to collaborate on oral multiple sclerosis therapy U.C.B. and BIIB announce a global collaboration to jointly develop and commercialize CDP323 for the treatment of relapsing-remitting multiple sclerosis...

12...PPMS: Small Study Holds Hope For chronic progressive patients with MS [PPMS]

13...COPAXONE New Data Confirmed Antibodies to Copaxone® Do Not Impact Its Established and Sustained Long-Term Efficacy in Multiple Sclerosis

14...COPAXONE WITH MITOXANTRONE: Very Active Multiple Sclerosis Patients Benefited From COPAXONE(R) Treatment Following Short-Term Induction With Mitoxantrone

15...AVONEX PRESS RELEASE FROM ECTRIMS
....treatment with AVONEX (Interferon beta-1a) promoted a statistically significant recovery of T1-black hole lesion volume by almost 24%....

16...LYRICA: Pfizer's Lyrica(Pregabalin Capsules) Approved in Europe for Difficult-to-Treat Nerve Pain.

17...MBP8298 shown to safely delay disease progression for five years in progressive MS patients with HLA-DR2 or HLA-DR4 immune response genes. BioMS Medical to present at the 22nd Congress of the European Com mittee for Treatment and Research in Multiple Sclerosis (ECTRIMS) :

18..."Testosterone gel proven to slow symptoms of MS...in small study": UCLA School of Medicine,

19...TYSABRI - Presented at ECTRIMS
Natalizumab (Tysabri) Reduces Brain Atrophy, Improves Cognition During Second Year of Multiple Sclerosis Treatment

20...TOVAXIN: New drug in the pipeline

21...REBIF: NEW FORMULATION: ONE-YEAR DATA FROM PHASE III TRIAL SHOW THAT NEW FORMULATION OF REBIF® OFFERS SUBSTANTIAL IMPROVEMENT IN TOLERABILITY AND IMMUNOGENICITY PROFILES...[click for full press release]:

22...NovaDel Announces Two CNS Oral Spray Drug Candidates in its Development Pipeline; Oral Spray Formulations of Tizanidine for Spasticity

23...SYMADEX...NEW DRUG ANNOUNCEMENT FROM ECTRIMS
Symadex Can Reverse Disease in Preclinical Multiple Sclerosis Animal Model

24...NICOTINAMIDE: "Daily Nicotinamide Shots May Protect MS Patients From Severe Disability"

25...Gene found that helps combat MS [MORE: BBC NEWS]
A gene that helps to stave off the effects of multiple sclerosis (MS) has been discovered by scientists. A Danish-UK team found that a known risk gene for MS, called DR2b, is always partnered by a twin gene - DR2a....

26...Novantrone (mitoxantrone)... Safety and Tolerability of Mitoxantrone for Worsening Multiple Sclerosis Appears Stable in Long Term: Presented at ECTRIMS...

27...Age Should Not Deter Multiple Sclerosis Diagnosis: Presented at ECTRIMS

SCROLL DOWN FOR THE STORIES BEHIND THE 27 HEADLINES ABOVE

DRUG ALERT #41 WILL BE SENT TO YOU THIS WEEKEND - Click here if you haven't requested our weekly Drug Alerts

Wednesday

THIS PAGE IS UNDER CONSTRUCTION...SOME RECENT HEADLINES HAVE NOT BEEN TRANFERRED TO THIS NEW SITE